CNTB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.8M
+1537.9%
169.0K
0
-100.0%
16.0K
-66.7%
48.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
2.8M
+1537.9%
169.0K
0
-100.0%
16.0K
-66.7%
48.0K
Operating Expenses
20.4M
+3.0%
19.8M
+27.4%
15.5M
-12.2%
17.7M
+31.3%
13.5M
R&D
16.3M
+8.3%
15.0M
+33.2%
11.3M
+1.5%
11.1M
+26.6%
8.8M
SG&A
4.1M
-13.6%
4.7M
+11.8%
4.2M
-35.5%
6.6M
+40.1%
4.7M
Operating Income
-17604000
+10.2%
-19607000
-26.3%
-15526000
+12.2%
-17677000
-31.7%
-13424000
EBITDA
-17443000
+10.3%
-19443000
-26.7%
-15345000
+12.3%
-17498000
-32.0%
-13253000
Net Income
-17284000
+10.9%
-19398000
-28.4%
-15109000
+12.2%
-17200000
-33.3%
-12899000
EPS (Basic)
$-0.27
+20.6%
$-0.34
-21.4%
$-0.28
+9.7%
$-0.31
-34.8%
$-0.23
EPS (Diluted)
$-0.27
+20.6%
$-0.34
-21.4%
$-0.28
+9.7%
$-0.31
-34.8%
$-0.23
Shares (Diluted)
62.9M
+11.2%
56.5M
+0.8%
56.1M
+0.6%
55.7M
+0.4%
55.5M
Connect Biopharma (CNTB) โ€” Financials